| dc.creator | Androudi S., Dastiridou A., Zierhut M. | en |
| dc.date.accessioned | 2023-01-31T07:31:38Z | |
| dc.date.available | 2023-01-31T07:31:38Z | |
| dc.date.issued | 2016 | |
| dc.identifier | 10.1007/978-3-540-75387-2_32 | |
| dc.identifier.isbn | 9783540753872; 9783540753858 | |
| dc.identifier.uri | http://hdl.handle.net/11615/70586 | |
| dc.description.abstract | Rituximab is a chimeric murine/human monoclonal antibody that targets CD20 peripheral B cells. It is structured from murine antihuman CD20 (Fab domain) that binds to the CD20 antigen on B lymphocytes, while the Fc domain (from human IgG1) binds complement and promotes cellular cytotoxicity. © Springer-Verlag Berlin Heidelberg 2016. | en |
| dc.language.iso | en | en |
| dc.source | Intraocular Inflammation | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958858954&doi=10.1007%2f978-3-540-75387-2_32&partnerID=40&md5=7e938f50aa90029c2eb90bf46f535a00 | |
| dc.subject | Springer Berlin Heidelberg | en |
| dc.title | New drugs | en |
| dc.type | bookChapter | en |
